| Name | Title | Contact Details |
|---|---|---|
Stephen Bedell |
Director, Enterprise IT/OT Security & Operations | Profile |
Denali Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. The company focuses on developing therapies for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders like Hunter syndrome. Denali employs around 422 professionals and utilizes proprietary blood-brain barrier transport technologies to meet the medical needs of patients with brain-related disorders. Denalis innovative approach includes four engineered transport vehicle systems: Enzyme Transport Vehicle (ETV), Antibody Transport Vehicle (ATV), Protein Transport Vehicle (PTV), and Oligonucleotide Transport Vehicle (OTV). These technologies enable the delivery of various therapeutic agents to the brain. The company collaborates with major pharmaceutical partners, including Sanofi, AbbVie, and Takeda, to enhance the development of its pipeline products, which include DNL310 for Hunter syndrome and DNL151 for Parkinson’s disease. Denalis mission is to advance therapies that address the underlying causes of neurodegeneration, emphasizing a commitment to rigorous science and patient-focused innovation.
Shoults Investments is a Des Moines, WA-based company in the Business Services sector.
Since 1968, Trendway has been developing design and service practices unsurpassed in the office furniture industry. Recognizing the need for products you can grow with, not outgrow, sets Trendway apart. And our dedication to establishing long-term
BackTrack is a Mentor, OH-based company in the Business Services sector.